Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $755.50
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard®...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue...
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 PR Newswire NEW YORK, Oct...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 PR Newswire NEW...
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test PR...
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care PR Newswire NEW YORK...
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit PR Newswire NEW YORK, Oct. 9...
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 PR Newswire NEW YORK, Oct. 8...
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players PR...
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer...
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK, Sept. 16...
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.